VIMAB Stock Overview
Engages in the management consulting activities in the areas of energy services, and industrial and environmental technology in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Vimab Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.50 |
| 52 Week High | SEK 23.60 |
| 52 Week Low | SEK 6.50 |
| Beta | 0.11 |
| 11 Month Change | 74.83% |
| 3 Month Change | 56.25% |
| 1 Year Change | 33.98% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.00% |
Recent News & Updates
Shareholder Returns
| VIMAB | SE Professional Services | SE Market | |
|---|---|---|---|
| 7D | -8.1% | 0.6% | -1.4% |
| 1Y | 34.0% | 25.4% | 20.7% |
Return vs Industry: VIMAB exceeded the Swedish Professional Services industry which returned 28.8% over the past year.
Return vs Market: VIMAB exceeded the Swedish Market which returned 25.9% over the past year.
Price Volatility
| VIMAB volatility | |
|---|---|
| VIMAB Average Weekly Movement | 34.1% |
| Professional Services Industry Average Movement | 5.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: VIMAB's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: VIMAB's weekly volatility has increased from 18% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 206 | Peter Fredell | vimabgroup.com |
Vimab Group AB (publ) engages in the management consulting activities in the areas of energy services, and industrial and environmental technology in Sweden and internationally. The company was incorporated in 2011 and is based in Motala, Sweden.
Vimab Group AB (publ) Fundamentals Summary
| VIMAB fundamental statistics | |
|---|---|
| Market cap | SEK 294.96m |
| Earnings (TTM) | -SEK 22.67m |
| Revenue (TTM) | SEK 376.34m |
0.8x
P/S Ratio-13.0x
P/E RatioIs VIMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMAB income statement (TTM) | |
|---|---|
| Revenue | SEK 376.34m |
| Cost of Revenue | SEK 258.81m |
| Gross Profit | SEK 117.52m |
| Other Expenses | SEK 140.20m |
| Earnings | -SEK 22.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 31.23% |
| Net Profit Margin | -6.03% |
| Debt/Equity Ratio | 177.5% |
How did VIMAB perform over the long term?
See historical performance and comparison